Protagonist Therapeutics (PTGX)

NASDAQ:PTGX

PTGX

Protagonist Therapeutics

RESEARCH TOOLSreports

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

735 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PTGX Analyst Ratings

Strong Buy

10 Buy

1 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Protagonist

Therapeutics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PTGX Stock 12 Month Forecast

Average Price Target

$112.00

▲(7.95% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Protagonist Therapeutics in the last 3 months. The average price target is $112.00 with a high forecast of $125.00 and a low forecast of $95.00. The average price target represents a 7.95% change from the last price of $103.75.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"43":"$43","126":"$126","63.75":"$63.8","84.5":"$84.5","105.25":"$105.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$125.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":112,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$112.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$95.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[43,63.75,84.5,105.25,126],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.67,105.31076923076924,106.95153846153846,108.5923076923077,110.23307692307692,111.87384615384616,113.51461538461538,115.15538461538462,116.79615384615384,118.43692307692308,120.0776923076923,121.71846153846154,123.35923076923078,{"y":125,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.67,104.31076923076924,104.95153846153846,105.5923076923077,106.23307692307692,106.87384615384616,107.51461538461538,108.15538461538462,108.79615384615384,109.43692307692308,110.0776923076923,110.71846153846154,111.35923076923078,{"y":112,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,103.67,103.00307692307692,102.33615384615385,101.66923076923077,101.0023076923077,100.33538461538461,99.66846153846154,99.00153846153846,98.33461538461539,97.6676923076923,97.00076923076924,96.33384615384615,95.66692307692307,{"y":95,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":46.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.99,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.15,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.21,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.62,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.64,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":83.05,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.24,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$125.00

Average Price Target$112.00

Lowest Price Target$95.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Kaveri Pohlman

Clear Street

$104→$116

Buy

11.81%

Upside

Reiterated

04/06/26

Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street

Brian Cheng

J.P. Morgan

$106

Buy

2.17%

Upside

Reiterated

03/25/26

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Olema Pharmaceuticals (NASDAQ: OLMA) and Medios AG (Other OTC: MEDOF)

Douglas Tsao

H.C. Wainwright

$117

Buy

12.77%

Upside

Reiterated

03/23/26

Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)

Etzer Darout

Barclays

$113→$119

Buy

14.70%

Upside

Assigned

03/19/26

Protagonist Therapeutics (PTGX) Receives a Buy from Barclays

Jonathan Wolleben

Citizens JMP

$112→$120

Buy

15.66%

Upside

Reiterated

03/19/26

Protagonist Therapeutics price target raised to $120 from $112 at CitizensProtagonist Therapeutics price target raised to $120 from $112 at Citizens

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

03/19/26

Analysts Are Bullish on These Healthcare Stocks: Medline (MDLN), Protagonist Therapeutics (PTGX)

Geoff Meacham

Citi

$115→$125

Buy

20.48%

Upside

Reiterated

03/19/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK), Valneva (NASDAQ: VALN) and Protagonist Therapeutics (NASDAQ: PTGX)

Yun Zhong

Wedbush

$100→$112

Buy

7.95%

Upside

Reiterated

03/19/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (NASDAQ: FDMT), Protagonist Therapeutics (NASDAQ: PTGX) and Trevi Therapeutics (NASDAQ: TRVI)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$107→$110

Buy

6.02%

Upside

Reiterated

03/19/26

Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink

Richard Law CFA

Goldman Sachs

$65→$95

Hold

-8.43%

Downside

Reiterated

03/03/26

Protagonist Therapeutics price target raised to $95 from $65 at Goldman SachsProtagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs

Tara Bancroft

TD Cowen

$90→$100

Buy

-3.61%

Downside

Assigned

02/26/26

Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$95

Buy

-8.43%

Downside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Julian Harrison

BTIG

$82

Buy

-20.96%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

$72→$112

Buy

7.95%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$72

Buy

-30.60%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Kaveri Pohlman

Clear Street

$104→$116

Buy

11.81%

Upside

Reiterated

04/06/26

Protagonist Therapeutics price target raised to $116 from $104 at Clear StreetProtagonist Therapeutics price target raised to $116 from $104 at Clear Street

Brian Cheng

J.P. Morgan

$106

Buy

2.17%

Upside

Reiterated

03/25/26

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX), Olema Pharmaceuticals (NASDAQ: OLMA) and Medios AG (Other OTC: MEDOF)

Douglas Tsao

H.C. Wainwright

$117

Buy

12.77%

Upside

Reiterated

03/23/26

Analysts Are Bullish on Top Healthcare Stocks: Protagonist Therapeutics (PTGX), MDxHealth (MDXH)

Etzer Darout

Barclays

$113→$119

Buy

14.70%

Upside

Assigned

03/19/26

Protagonist Therapeutics (PTGX) Receives a Buy from Barclays

Jonathan Wolleben

Citizens JMP

$112→$120

Buy

15.66%

Upside

Reiterated

03/19/26

Protagonist Therapeutics price target raised to $120 from $112 at CitizensProtagonist Therapeutics price target raised to $120 from $112 at Citizens

Srikripa Devarakonda

Truist Financial

―

Buy

―

Reiterated

03/19/26

Analysts Are Bullish on These Healthcare Stocks: Medline (MDLN), Protagonist Therapeutics (PTGX)

Geoff Meacham

Citi

$115→$125

Buy

20.48%

Upside

Reiterated

03/19/26

Analysts Offer Insights on Healthcare Companies: Stoke Therapeutics (NASDAQ: STOK), Valneva (NASDAQ: VALN) and Protagonist Therapeutics (NASDAQ: PTGX)

Yun Zhong

Wedbush

$100→$112

Buy

7.95%

Upside

Reiterated

03/19/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: 4D Molecular Therapeutics (NASDAQ: FDMT), Protagonist Therapeutics (NASDAQ: PTGX) and Trevi Therapeutics (NASDAQ: TRVI)

Unknown Analyst

Leerink Partners

Not Ranked

Leerink Partners

$107→$110

Buy

6.02%

Upside

Reiterated

03/19/26

Protagonist price target raised to $110 from $107 at LeerinkProtagonist price target raised to $110 from $107 at Leerink

Richard Law CFA

Goldman Sachs

$65→$95

Hold

-8.43%

Downside

Reiterated

03/03/26

Protagonist Therapeutics price target raised to $95 from $65 at Goldman SachsProtagonist Therapeutics price target raised to $95 from $65 at Goldman Sachs

Tara Bancroft

TD Cowen

$90→$100

Buy

-3.61%

Downside

Assigned

02/26/26

Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target

Unknown Analyst

Jefferies

Not Ranked

Jefferies

$95

Buy

-8.43%

Downside

Reiterated

12/19/25

Jefferies Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)

Julian Harrison

BTIG

$82

Buy

-20.96%

Downside

Reiterated

11/03/25

Analysts Offer Insights on Healthcare Companies: Protagonist Therapeutics (NASDAQ: PTGX) and Perspective Therapeutics (NYSE MKT: CATX)

Evan Seigerman

BMO Capital

$72→$112

Buy

7.95%

Upside

Reiterated

10/13/25

Protagonist Therapeutics (PTGX) Gets a Buy from BMO Capital

Unknown Analyst

Roth MKM

Not Ranked

Roth MKM

$72

Buy

-30.60%

Downside

Initiated

09/17/25

Protagonist Therapeutics (PTGX) Initiated with a Buy at Roth MKM

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Protagonist Therapeutics

3 Months

xxx

Success Rate

13/15 ratings generated profit

Average Return

+16.20%

reiterated a xxx

rating 15 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 86.67% of your transactions generating a profit, with an average return of +16.20% per trade.

1 Year

Jonathan WollebenCitizens JMP

Success Rate

24/24 ratings generated profit

Average Return

+83.41%

reiterated a buy rating 21 days ago

Copying Jonathan Wolleben's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +83.41% per trade.

2 Years

xxx

Success Rate

24/24 ratings generated profit

Average Return

+200.28%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +200.28% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PTGX Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PTGX has received 32 Buy Ratings, 33 Hold Ratings, and 0 Sell Ratings. PTGX average Analyst price target in the past 3 months is 112.00.

Each month's total comprises the sum of three months' worth of ratings.

PTGX Financial Forecast

PTGX Earnings Forecast

Next quarter’s earnings estimate for PTGX is -$0.49 with a range of -$1.23 to $0.50. The previous quarter’s EPS was -$0.69. PTGX beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PTGX has Performed in-line its overall industry.

PTGX Sales Forecast

Next quarter’s sales forecast for PTGX is $12.21M with a range of $0.00 to $93.80M. The previous quarter’s sales results were $7.44M. PTGX beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PTGX has Performed in-line its overall industry.

PTGX Stock Forecast FAQ

What is PTGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Protagonist Therapeutics’s 12-month average price target is 112.00.

What is PTGX’s upside potential, based on the analysts’ average price target?

Protagonist Therapeutics has 7.95% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is PTGX a Buy, Sell or Hold?

Protagonist Therapeutics has a consensus rating of Strong Buy which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.

What is Protagonist Therapeutics’s price target?

The average price target for Protagonist Therapeutics is 112.00. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $125.00 ,the lowest forecast is $95.00. The average price target represents 7.95% Increase from the current price of $103.75.

What do analysts say about Protagonist Therapeutics?

Protagonist Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of PTGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

PTGX Analyst Ratings

PTGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Protagonist Therapeutics

PTGX Analyst Recommendation Trends

PTGX Financial Forecast

PTGX Earnings Forecast

PTGX Sales Forecast

PTGX Stock Forecast FAQ

Detailed List of Analyst Forecasts